Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F86652036%3A_____%2F15%3A00457394" target="_blank" >RIV/86652036:_____/15:00457394 - isvavai.cz</a>

Result on the web

<a href="http://dx.doi.org/10.1016/j.lungcan.2015.09.021" target="_blank" >http://dx.doi.org/10.1016/j.lungcan.2015.09.021</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.lungcan.2015.09.021" target="_blank" >10.1016/j.lungcan.2015.09.021</a>

Result language

angličtina

Original language name

Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma

Original language description

Objectives: Malignant mesothelioma (MM) is a highly aggressive tumor with poor prognosis. A major challenge is the development and application of early and highly reliable diagnostic marker(s). Serum biomarkers, such as 'soluble mesothelin-related proteins' (SMRPs), is the most studied and frequently used in MM. However, the low sensitivity of SMRPs for early MM limits its value; therefore, additional biomarkers are required. In this study, two epigenetically regulated markers in MM (microRNA-126, miR126, and methylated thrombomodulin promoter, Met-TM) were combined with SMRPs and evaluated as a potential strategy to detect MM at an early stage. Materials and methods: A total of 188 subjects, including 45 MM patients, 99 asbestos-exposed subjects, and44 healthy controls were prospectively enrolled, serum samples collected, and serum levels of SMRPs, miR-126 and Met-TM evaluated. Logistic regression analysis was performed to evaluate the diagnostic value of the three biomarkers. Using

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

EB - Genetics and molecular biology

OECD FORD branch

—

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2015

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Lung Cancer

ISSN

0169-5002

e-ISSN

—

Volume of the periodical

90

Issue of the periodical within the volume

3

Country of publishing house

IE - IRELAND

Number of pages

8

Pages from-to

457-464

UT code for WoS article

000366873700013

EID of the result in the Scopus database

—